LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Anavex Life Sciences Corp

Closed

SectorHealthcare

8.24 6.05

Overview

Share price change

24h

Current

Min

7.73

Max

8.24

Key metrics

By Trading Economics

Income

915K

-11M

EPS

-0.132

Employees

42

EBITDA

-779K

-13M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+266.32% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

-58M

669M

Previous open

2.19

Previous close

8.24

News Sentiment

By Acuity

20%

80%

46 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Anavex Life Sciences Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 cze 2025, 14:31 UTC

Earnings

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 cze 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 cze 2025, 20:33 UTC

Earnings

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 cze 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 cze 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 cze 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 cze 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 cze 2025, 16:35 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 cze 2025, 16:34 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 cze 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 cze 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 cze 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 cze 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 cze 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 cze 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 cze 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 cze 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 cze 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 cze 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 cze 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 cze 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 cze 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 cze 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 cze 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 cze 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 cze 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 cze 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 cze 2025, 14:12 UTC

Earnings

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 cze 2025, 14:09 UTC

Earnings

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Peer Comparison

Price change

Anavex Life Sciences Corp Forecast

Price Target

By TipRanks

266.32% upside

12 Months Forecast

Average 28.5 USD  266.32%

High 42 USD

Low 15 USD

Based on 2 Wall Street analysts offering 12 month price targets forAnavex Life Sciences Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

8.275 / 9.312Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

46 / 380 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Interest expense on debt

EBITDA

Operating profit

$

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.